SARS-CoV-2 antibody and T cell responses one year after COVID-19 and the booster effect of vaccination: A prospective cohort study

Ong David, 2021, How to interpret and use COVID-19 serology and immunology tests, Clin Microbiol Infect, 27, 981, 10.1016/j.cmi.2021.05.001 Khoury David, 2021, Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection, Nat Med, 27, 1205, 10.1038/s41591-021-01377-8 Markus, 2020, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, 181, 271, 10.1016/j.cell.2020.02.052 Filippo, 2020, ACE2: the major cell entry receptor for SARS-CoV-2, Lung, 198, 867, 10.1007/s00408-020-00408-4 Takuya, 2020, Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19, Cell, 183, 158, 10.1016/j.cell.2020.08.017 Alba, 2020, Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals, Cell, 181, 1489, 10.1016/j.cell.2020.05.015 Shaohua, 2020, Clinical and pathological investigation of patients with severe COVID-19, JCI Insight, 5, 1 Altmann Daniel, 2020, SARS-CoV-2 T cell immunity: specificity, function, durability, and role in protection, Sci Immunol, 5, 2 Daniela, 2020, Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome, Sci Immunol, 5, 1 Oja Anna, 2020, Divergent SARS-CoV-2-specific T- and B-cell responses in severe but not mild COVID-19 patients, Eur J Immunol, 50, 1998, 10.1002/eji.202048908 Urra, 2020, Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients, Clin Immunol, 217, 1, 10.1016/j.clim.2020.108486 Antonio, 2021, SARS-CoV-2-specific T cells in infection and vaccination, Cell Mol Immunol, 1 Alessandro, 2021, Adaptive immunity to SARS-CoV-2 and COVID-19, Cell, 184, 861, 10.1016/j.cell.2021.01.007 Geers, 2021, SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees, Sci Immunol, 6, 1, 10.1126/sciimmunol.abj1750 Alison, 2021, Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals, Cell Rep Med, 2, 1 Delphine, 2021, Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization, Nature, 596, 276, 10.1038/s41586-021-03777-9 Jordan Stanley, 2021, T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals, Cell Mol Immunol, 1 Yun, 2020, Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection, Front Med, 14, 746, 10.1007/s11684-020-0822-5 Tatjana, 2021, T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals, Sci Transl Med, 13, 1 Jianmin, 2021, Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection, Nat Immunol, 22, 620, 10.1038/s41590-021-00902-8 Lin, 2021, Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection, Nat Commun, 12, 1 Catherine, 2020, Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection, Sci Immunol, 5, 1 Natalia, 2021, Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6–8 months after the infection, Med, 2, 281, 10.1016/j.medj.2021.02.001 Baweleta, 2020, Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients, Sci Immunol, 5, 1 Casado, 2021, Progressive and parallel decline of humoral and T-cell immunity in convalescent healthcare workers with asymptomatic or mild-to-moderate severe acute respiratory syndrome coronavirus 2 infection, J Infect Dis, 224, 241, 10.1093/infdis/jiab242 Gaëlle, 2021, Persistent cellular immunity to SARS-CoV-2 infection, J Exp Med, 218, 1 Dan, 2021, Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection, Science, 371, 1, 10.1126/science.abf4063 Ugur, 2020, COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses, Nature, 586, 594, 10.1038/s41586-020-2814-7 Stephenson, 2021, Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19, JAMA, 10.1001/jama.2021.3645 Anderson, 2020, Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults, N Engl J Med, 383, 2427, 10.1056/NEJMoa2028436 Ramasamy Maheshi, 2020, Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial, Lancet, 396, 1979, 10.1016/S0140-6736(20)32466-1 Ong David, 2021, SARS-CoV-2 antibody response dynamics and heterogeneous diagnostic performance of four serological tests and a neutralization test in symptomatic healthcare workers with non-severe COVID-19, J Clin Virol, 141, 1 Johannes, 2012, Fiji: an open-source platform for biological-image analysis, Nat Methods, 9, 676, 10.1038/nmeth.2019 Patrick, 2018, Correlation coefficients: appropriate use and interpretation, Anesth Analg, 126, 1763, 10.1213/ANE.0000000000002864 National Institute for Public Health and the Environment (RIVM), COVID-19 vaccination regulations. [cited 02/10/2021]; Available at: https://www.rivm.nl/en/covid-19-vaccination/vaccines/efficacy-and-protection Cohen, 2021, Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells, Cell Rep Med, 2 Tyler, 2021, SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation, Clin Transl Immunol, 10, 1 Lin, 2021, Persistence of antibody and cellular immune responses in coronavirus disease 2019 patients over nine months after infection, J Infect Dis, 224, 586, 10.1093/infdis/jiab255 Takehiro, 2020, Sex differences in immune responses that underlie COVID-19 disease outcomes, Nature, 588, 315, 10.1038/s41586-020-2700-3 National Institute for Public Health and the Environment (RIVM), weekly SARS-CoV-2 figures. [cited 02/10/2021]; Available at: https://www.rivm.nl/en/coronavirus-covid-19/weekly-figures Goel, 2021, Distinct antibody and memory B cell responses in SARSCoV-2 naïve and recovered individuals following mRNA vaccination, Sci Immunol, 6, 1, 10.1126/sciimmunol.abi6950 Maria, 2021, Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine, Lancet, 397, 1178, 10.1016/S0140-6736(21)00502-X Iivo, 2021, An outbreak caused by the SARS-CoV-2 Delta variant (B. 1. 617. 2) in a secondary care hospital in Finland, Eurosurveillance, 26, 1 Williams, 2021, An outbreak caused by the SARS-CoV-2 Delta (B. 1.617. 2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria, London, England, April 2021, Eurosurveillance, 26, 1, 10.2807/1560-7917.ES.2021.26.27.2100626 Kendra, 2021, SARS-CoV-2 B1. 617. 2 (Delta) variant COVID-19 outbreak associated with a gymnastics facility — Oklahoma, April – May 2021, Morb Mortal Wkly Rep, 70, 1004, 10.15585/mmwr.mm7028e2 Samuel, 2021, Rapid spread of the SARS-CoV-2 Delta variant in some, Eurosurveillance, 26, 1 Lopez, 2021, Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant, N Engl J Med, 385, 585, 10.1056/NEJMoa2108891